Search Journal-type in search term and press enter
Social Media-Follow Southwest Journal of Pulmonary and Critical Care on Facebook and Twitter

Articles from Other Journals

(Click on the title to go to the article summary, most recent first, date posted at end)

FDA Warns About Increased Risk of Ruptures or Tears in the Aorta Blood Vessel With Fluoroquinolone Antibiotics in Certain Patients. US Food and Drug Administration. December 20, 2018. (12/22/18).

Optimizing Home Oxygen Therapy. An Official American Thoracic Society Workshop Report. Jacobs SS, Lederer DJ, Garvey CM, et al. Ann Am Thorac Soc. 2018 Dec;15(12):1369-81. (12-13-18)

FDA Approves First Treatment for Lambert-Eaton Myasthenic Syndrome, A Rare Autoimmune Disorder. FDA News Releast. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm627093.htm (12-4-18)

Does Point-of-Care Ultrasonography Improve Clinical Outcomes in Emergency Department Patients with Undifferentiated Hypotension? Atkinson PR, Milne J, Diegelmann L, et al. Ann Emerg Med. 2018 Oct;72(4):478-89. (11-8-18)

E-cigarette Use and Subsequent Smoking Frequency Among Adolescents. Barrington-Trimis JL, Kong G, Leventhal AM, et al. Pediatrics. November 05, 2018. [Epub ahead of print] (11-5-18)

Changes in Prevalence of Health Care-Associated Infections in U.S. Hospitals. Magill SS, O'Leary E, Janelle SJ, et al. N Engl J Med. 2018 Nov 1;379(18):1732-1744. (11-1-18)

Benefits and Harms of Antihypertensive Treatment in Low-Risk Patients with Mild Hypertension. Sheppard JP, Stevens S, Stevens R, Martin U, Mant J, Hobbs FDR, McManus RJ. JAMA Intern Med. October 29, 2018. (11-30-18)

Prevalence of Financial Conflicts of Interest Among Authors of Clinical Guidelines Related to High-Revenue Medications. Khan R, Scaffidi MA, Rumman A, Grindal AW, Plener IS, Grover SC. JAMA Intern Med. 2018 Oct 29. and Evaluation of Industry Relationships Among Authors of Clinical Practice Guidelines in Gastroenterology. CombsTR, Scott J, Jorski A, Heavener T, Vassar M. JAMA Intern Med. 2018 Oct 29. (10-30-18).

Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. Hayden FG, Sugaya N, Hirotsu N, et al. N Engl J Med. 2018 Sep 6;379(10):913-23. (10-25-18)

Assessment of Industry Data on Pulmonary and Immunosuppressive Effects of IQOS. Moazed F, Chun L, Matthay MA, Calfee CS, Gotts J.. Tob Control. 2018 Aug 29. pii: tobaccocontrol-2018-054296. [Epub ahead of print] (9-24-18)

Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. McNeil JJ, Nelson MR, Woods RL, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018 Sep 16. [Epub ahead of print] (9-20-18)

Improved Empirical Antibiotic Treatment of Sepsis After an Educational Intervention: The ABISS-Edusepsis Study. Ferrer R, Martínez ML, Gomà G, et al. Crit Care. 2018 Jun 22;22(1):167. (8-31-18).

Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial. Bergeron A, Chevret S, Granata A, et al. JAMA 2017;318(6):557-566. (8-8-18)

Depression, Antidepressant Use, and Risk of Venous Thromboembolism: Systematic Review and Meta-Analysis Of Published Observational Evidence. Kunutsor SK Seidu S, Khunti K. Ann Med. 2018 Jul 12:1-17. (7-30-18)

Electronic Health Records Associated with Lower Hospital Mortality After Systems Have Time to Mature. Lin SC, Jha AK, Adler-Milstein J. Health Aff (Millwood). 2018 Jul;37(7):1128-1135. (7-12-18)

Sodium Bicarbonate Therapy for Patients with Severe Metabolic Acidaemia in the Intensive Care Unit (BICAR-ICU): A Multicentre, Open-Label, Randomised Controlled, Phase 3 Trial. Jaber S, Paugam C, Futier E, et al. Lancet. 2018 Jun 14. pii: S0140-6736(18)31080-8. (7-6-18)

Combined Analysis of Asthma Safety Trials of Long-Acting β2-Agonists. Busse WW, Bateman ED, Caplan AL, Kelly HW, O'Byrne PM, Rabe KF, Chinchilli VM. N Engl J Med. 2018 Jun 28;378(26):2497-2505. (7-5-18)

Continuity of Care with Doctors-A Matter of Life and Death? A Systematic Review of Continuity of Care and Mortality. Pereira Gray D, Sidaway-Lee K, White E, Thorne A, Evans PH. BMJ Open. 2018 Jun 28;8(6):e021161. (7-3-18)

Minimally Invasive Lung Cancer Surgery Performed by Thoracic Surgeons as Effective as Thoracotomy. Boffa DJ, Kosinski AS, Furnary AP, et al. J Clin Oncol. 2018 May 23:JCO2018778977. [Epub ahead of print] (6-30-18)

Serotonergic Antidepressant Use and Morbidity and Mortality Among Older Adults with COPD. Vozoris NT, Wang X, Austin PC, et al. Eur Respir J  2018 Jun 26. [Epub ahead of print] (6-27-18)

Associations Between American Board of Internal Medicine Maintenance of Certification Status and Performance on a Set of Healthcare Effectiveness Data and Information Set Process Measures. Gray B, Vandergrift J, Landon B, Reschovsky J, Lipner R. Ann Intern Med. 2018 Jun 12. [Epub ahead of print] (6-17-18)

Effects on Abstinence of Nicotine Patch Treatment Before Quitting Smoking: Parallel, Two Arm, Pragmatic Randomised Trial. The preloading investigators. BMJ. 2018 Jun 13;361:k2164. (6-15-18)

Associations Between American Board of Internal Medicine Maintenance of Certification Status and Performance on a Set of Healthcare Effectiveness Data and Information Set Process Measures. Gray B, Vandergrift J, Landon B, Reschovsky J, Lipner R. Ann Intern Med. 2018. June 11, 2018. [Epub ahead of print] (6-12-18)

Impact of Primary Care Intensive Management on High-Risk Veterans' Costs and Utilization: A Randomized Quality Improvement Trial. Yoon J, Chang E, Rubenstein LV, Park A, Zulman DM, Stockdale S, Ong MK, Atkins D, Schectman G, Asch SM. Ann Intern Med. 2018 Jun 5. [Epub ahead of print] (6-7-18)

Effect of Increased Inpatient Attending Physician Supervision on Medical Errors, Patient Safety, and Resident Education: A Randomized Clinical Trial. Finn KM, Metlay JP, Chang Y, Nagarur A, Yang S, Landrigan CP, Iyasere C.JAMA Intern Med. 2018 Jun 4 [Epub ahead of print]. (6-6-18)

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. Sparano JA, Gray RJ, Makower DF, et al. N Engl J Med. 2018; June 3. (6-4-18)

Effect of Use of a Bougie vs Endotracheal Tube and Stylet on First-Attempt Intubation Success Among Patients with Difficult Airways Undergoing Emergency Intubation: A Randomized Clinical Trial. Driver BE, Prekker ME, Klein LR, Reardon RF, Miner JR, Fagerstrom ET, Cleghorn MR, McGill JW, Cole JB. JAMA. 2018 May 16. (6-1-18)

Association of Pharmaceutical Industry Marketing of Opioid Products to Physicians With Subsequent Opioid Prescribing. Hadland SE, Cerdá M, Li Y, Krieger MS, Marshall BDL. JAMA Int Med 2018; May 14. [Epub ahead of print] (5-14-18)

Low-Dose CT for the Diagnosis of Pneumonia in Elderly Patients: A Prospective, Interventional Cohort Study. Prendki V, Scheffler M, Huttner B, et al. Eur Respir J. 2018 Apr 12. pii: 1702375. [Epub ahead of print] (5-4-18)

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. N Engl J Med. 2018 Apr 16 [Epub ahead of print] (4-17-18)

Four-gene Pan-African Blood Signature Predicts Progression to Tuberculosis. Suliman S, Thompson E, Sutherland J, et al. Am J Respir Crit Care Med. 2018 Apr 6. [Epub ahead of print] (4-10-18)

A Time-Motion Study of Primary Care Physicians' Work in the Electronic Health Record Era. Young RA, Burge SK, Kumar KA, Wilson JM, Ortiz DF. Fam Med. 2018 Feb;50(2):91-9. (3-28-18)

Impact of Temporary Methotrexate Discontinuation for 2 Weeks on Immunogenicity of Seasonal Influenza Vaccination in Patients with Rheumatoid Arthritis: A Randomised Clinical Trial. Park JK, Lee YJ, Shin K, Ha YJ, et al.  Ann Rheum Dis. 2018 Mar 23. pii: annrheumdis-2018-213222. (3-27-18)

Quantifying Population-Level Health Benefits and Harms of E-Cigarette Use in the United States. Soneji SS, Sung HY, Primack BA, Pierce JP, Sargent JD. PLoS One. 2018 Mar 14;13(3):e0193328. (3-15-18)

Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: The SPACE randomized clinical trial. Krebs EE, Gravely A, Nugent S, et al. JAMA. 2018 Mar 6;319(9):872-82. (3-6-18)

Adolescent Exposure to Toxic Volatile Organic Chemicals from E-Cigarettes. Rubinstein ML, Delucchi K, Benowitz NL, et al. Pediatrics. 2018;141(4):e20173557. (3/5/18)

Electronic Cigarette Use and Progression from Experimentation to Established Smoking. Chaffee BW, Watkins SL, Glantz SA. Pediatrics. 2018;141(4):e20173594. (3/5/18)

Association of Cigarette, Cigar, and Pipe Use With Mortality Risk in the US Population. Christensen CH, Rostron B, Cosgrove C, et al. Association of Cigarette, Cigar, and Pipe Use With Mortality Risk in the US Population. JAMA Intern Med. 2018 Feb 19. [Epub ahead of print] (2-22-18)

Cleaning at Home and at Work in Relation to Lung Function Decline and Airway Obstruction. Svanes Ø, Bertelsen RJ, Lygre SH, et al.  Am J Respir Crit Care Med. 2018 Feb 16. [Epub ahead of print] (2-20-18)

Long-term Use of Inhaled Corticosteroids in COPD and the Risk of Fracture. Gonzalez AV, Coulombe J, Ernst P, Suissa S. Chest. 2018;153(2):321-8. (2-15-18)

Prevention of Ventilator-Associated Pneumonia: The Multimodal Approach of the Spanish ICU “Pneumonia Zero” Program.  Álvarez-Lerma F, Palomar-Martínez M, Sánchez-García M, et al. Crit Care Med 2018;46:181-8. (2-8-18) 

Progressive Massive Fibrosis in Coal Miners From 3 Clinics in Virginia. Blackley DJ, Reynolds LE, Short C, Carson R, Storey,E, Halldin,CN, Laney AS. JAMA 2018;319(5):50-1. (2-6-18)

Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. Hackshaw A,  Morris JK, Boniface S, Tang JL, Milenković D. BMJ. 2018;360:j5855. (1-27-18)

Comparison of observed harms and expected mortality benefit for persons in the veterans health affairs lung cancer screening demonstration project. Caverly TJ, Fagerlin A, Wiener RS, Slatore CG, Tanner NT, Yun S, Hayward R. JAMA Intern Med. 2018 Jan 22. [Epub ahead of print] (1-22-18)

Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer. Kim ES, Baran AM, Mondo EL, et al. PLoS One. 2017 Dec 11;12(12):e0189410. (1-8-18)

Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: A nested case-control study. Wang MT, Liou JT, Lin CW, Tsai CL, Wang YH, Hsu YJ, Lai JH. JAMA Intern Med. 2018 Jan 2. [Epub ahead of print] (1-5-18)

Previously selected articles that were thought important but had received little attention were summarized under our “News” section. However, the work of publication (review, DOAJ, doi, social media, etc.) has become too arduous to do justice to these publications. Therefore, we are beginning a new section titled “News from Other Journals” where selected articles are briefly summarized. Important articles that are published in journals commonly read by pulmonologists, intensivists or sleep physicians will not necessarily be reviewed but articles that are in general medicine journals or lower impact journals that might be of interest to the practicing physician are selected. As always, there will be links to the article via CrossRef and/or PubMed.

------------------------------------------------------------------------------------

Thursday
Nov012018

Changes in Prevalence of Health Care-Associated Infections in U.S. Hospitals

Magill SS, O'Leary E, Janelle SJ, et al. N Engl J Med. 2018 Nov 1;379(18):1732-1744. [CrossRef] [PubMed]

Health care-associated infections (HCAI) have been associated with poorer outcomes including increased mortality. Programs have been initiated by Centers for Medicare and Medicaid Services (CMS) to reduce reimbursement to hospitals based on their HCAI rate. The authors conducted a point-prevalence self-reported survey of selected US hospitals and compared it to 2011 data. The results showed that 3.2% of hospitalized patients had HACI in 2015 which was significantly lower than the 4.0% reported in 2011. However, mortality did not differ. The results suggest that the hospital-reported HACI has declined but was not associated with the dramatic reduction in mortality claimed by CMS.

Tuesday
Oct302018

Benefits and Harms of Antihypertensive Treatment in Low-Risk Patients with Mild Hypertension

Sheppard JP, Stevens S, Stevens R, Martin U, Mant J, Hobbs FDR, McManus RJ. JAMA Intern Med. October 29, 2018. [CrossRef]

Evidence to support initiation of pharmacologic treatment in low-risk patients with mild hypertension is inconclusive, with previous trials underpowered to demonstrate benefit. Clinical guidelines across the world are contradictory. In this longitudinal cohort study, data were extracted from the Clinical Practice Research Datalink, from January 1, 1998, through September 30, 2015, for patients aged 18 to 74 years who had mild hypertension (untreated blood pressure of 140/90-159/99 mm Hg) and no previous treatment. A total of 19,143 treated patients were matched to 19,143 similar untreated patients. During a median follow-up period of 5.8 years, no evidence of an association was found between antihypertensive treatment and mortality. Treatment was associated with an increased risk of adverse events, including hypotension, syncope, electrolyte abnormalities, and acute kidney injury. The authors found no evidence to support guideline recommendations that encourage initiation of treatment in patients with low-risk mild hypertension but an increased risk of adverse events.

Tuesday
Oct302018

Prevalence of Financial Conflicts of Interest Among Authors of Clinical Guidelines Related to High-Revenue Medications/Evaluation of Industry Relationships Among Authors of Clinical Practice Guidelines in Gastroenterology

Khan R, Scaffidi MA, Rumman A, Grindal AW, Plener IS, Grover SC.  JAMA Intern Med. 2018 Oct 29. [CrossRef]

Combs TR, Scott J, Jorski A, Heavener T, Vassar M. JAMA Intern Med. 2018 Oct 29. [CrossRef]

Two studies appeared in JAMA Internal Medicine in yesterday’s JAMA Internal Medicine on conflict of interest amongst guideline writing committees. The first study examined financial conflicts of interest of authors writing clinical practice guidelines recommending high-priced medications. Of the 160 authors, 50 (31.3%) declared payment from companies marketing the medication recommended in the guideline. An additional 41 authors (25.6%) received, but did not disclose, payments from the marketers. In the second study, payments disclosed in gastroenterology clinical guidelines often differed from those reported by the Centers for Medicare & Medicaid Services (CMS). 44 of 83 (53%) authors received industry payments but only 16 (19%) fully disclosed their financial conflicts of interest. Various organizations, including the Institute of Medicine, recommends that guideline development teams be composed of at most 50% authors who have financial relationships to disclose, and recommends abstaining from financial conflicts for a period of 1 year following guideline publication. These studies would seem to indicate that those writing clinical practice guidelines are not adhering to these policies.

Thursday
Oct252018

Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents

Hayden FG, Sugaya N, Hirotsu N, et al. N Engl J Med. 2018 Sep 6;379(10):913-23. [CrossRef] [PubMed]

Baloxavir marboxil is a selective inhibitor of influenza cap-dependent endonuclease and has shown therapeutic activity in preclinical models of influenza A and B virus infections, including strains resistant to current antiviral agents. The authors conducted two randomized, double-blind, controlled trials involving otherwise healthy outpatients with acute uncomplicated influenza. A dose-ranging (10 to 40 mg) phase 1 placebo-controlled trial was initially conducted. This was followed by a phase 3 trial comparing baloxavir and the neuraminidase inhibitor, oseltamivir, in a single dose during the 2016-7 season. The primary efficacy end point was the time to alleviation of influenza symptoms in the intention-to-treat infected population. In the phase 2 trial, the median time to alleviation of influenza symptoms was 23.4 to 28.2 hours shorter in the baloxavir groups than in the placebo group (P<0.05). In the phase 3 trial, the intention-to-treat infected population included 1064 patients; 84.8 to 88.1% of patients in each group had influenza A(H3N2) infection. The time to alleviation of symptoms was similar with baloxavir and oseltamivir. Baloxavir was associated with greater reductions in viral load 1 day after initiation of the regimen than placebo or oseltamivir. Adverse events did not differ in the placebo, oseltamivir and baloxair groups. The emergence of polymerase acidic protein variants with I38T/M/F substitutions conferring reduced susceptibility to baloxavir occurred in 2.2% and 9.7% of baloxavir recipients in the phase 2 trial and phase 3 trial, respectively. The authors conclude that single-dose baloxavir was without evident safety concerns, was superior to placebo in alleviating influenza symptoms, and was superior to both oseltamivir and placebo in reducing the viral load 1 day after initiation of the trial regimen in patients with uncomplicated influenza. Based on this study, The US Food and Drug Administration (FDA) approved baloxavir marboxil tablets (Xofluza, Shionogi) for the treatment of acute uncomplicated influenza in people age 12 years and older who have been symptomatic for no more than 48 hours.

Monday
Sep242018

Assessment of Industry Data on Pulmonary and Immunosuppressive Effects of IQOS

Moazed F, Chun L, Matthay MA, Calfee CS, Gotts J.. Tob Control. 2018 Aug 29. pii: tobaccocontrol-2018-054296. [Epub ahead of print] [CrossRef] [PubMed]

Philip Morris International has submitted a modified risk tobacco product (MRTP) application to the US Food and Drug Administration in 2016 in which it purports that its heated tobacco product, I-Quit-Ordinary-Smoking (IQOS), is associated with reduced harm compared with conventional cigarettes. The authors reviewed Philip Morris International’s MRTP application to assess the pulmonary and immune toxicities associated with IQOS use in both animal and human studies. Among rats exposed to IQOS, there was evidence of pulmonary inflammation and immunomodulation. In human users, there was no evidence of improvement in pulmonary inflammation or pulmonary function in cigarette smokers who were switched to IQOS. The authors conclude that IQOS is associated with significant pulmonary and immunomodulatory toxicities with no detectable differences between conventional cigarette smokers and those who were switched to IQOS in Philip Morris International’s studies. Based on the limited available data to date, IQOS use does not appear to significantly differ from conventional cigarettes in causing pulmonary and immunomodulatory harm.